Tag: diabetic foot

Ninety-Five Thousand Hands on the Work: A #Citation Milestone, and Why This is Always a Team Sport #ActAgainstAmputation #LimbPreservation @ALPSLimb @KeckSchool_USC @USC_Vascular

Google Scholar ticked over to 95,006 citations overnight. The number is real — the story behind it isn't mine. An h-index of 134 and an i10-index of 568 reflect 568 conversations between collaborators, residents, fellows, patients, and friends. A note on what citations actually are, why limb preservation is and always will be a team sport, and gratitude to everyone whose hand has been on the work.

0

When it comes to #DiabeticFoot infections, Moderate ≠ Severe: New #Biomarker Data Reignite and Support the Case for Splitting Categories #IDSA #WIfI #ActAgainstAmputation

An email from Ben Lipsky brings new biomarker data — IL-17, IL-12p70, HMGB1, IL-8, CRP — that may be the strongest case yet for splitting "moderate" and "severe" diabetic foot infections in the IDSA and WIfI classification.

0

The Lennon and McCartney of the Diabetic Foot, Remastered: Rescuing a Hilarious 2008 @ABoultonMD Toast for #Malvern40 #ActAgainstAmputation #DFCon #LimbPreservation @ALPSLimb

Eighteen years ago, Larry Lavery and I stood up at the Malvern Diabetic Foot Meeting dinner and performed four Beatles rewrites in honor of Andrew Boulton. It brought the house down. As Malvern turns 40, here are the videos — writers' room, performance, applause, and Abbey walls — rescued, remastered, and archived for the record.

0

Absence of Evidence or Evidence of Absence? @SennevilleEric and Ben Lipsky on Bone Biopsy in Diabetic Foot Osteomyelitis #DFO #osteomyelitis #DFU #DFI #ActAgainstAmputation

Senneville and Lipsky return with a measured rejoinder in Clinical Infectious Diseases (April 2026), arguing that the Lagrand trial shows the absence of evidence of superiority — not definitive equivalence — between ulcer-bed and bone biopsy for guiding antibiotic therapy in diabetic foot osteomyelitis.

0

“Spooky Action at a Distance”: The Most Comprehensive Review Yet of Physiologic Neuromodulation for Limb Preservation #ActAgainstAmputation #Neuromodulation #SpinalCordStimulation #CLTI @BurnsTrauma @KeckSchool_USC @ResearchatUSC @USC

Our new paper in Burns and Trauma presents the most comprehensive review yet of spooky action at a distance therapies for diabetic limb preservation — from spinal cord stimulation and splenic ultrasound to remote ischemic conditioning and tibial transport. Five modalities, three mechanistic pathways, one shared destination: tissue repair at a distance.

0

Dosing Walking Like a Drug: An AI Chatbot for Diabetic Foot Remission Following Limb Reconstruction #ActAgainstAmputation #DiabeticFoot #Remission #AI #Chatbot @SensorsMDPI @KeckSchool_USC @ALPSLimb @USC_Vascular

A new protocol paper in Sensors describes a chatbot that doses walking like a drug for patients in diabetic foot remission.

0

You Are What You Eat — And That’s Pretty Inflammatory: A New Composite Biomarker for DFU Risk #ActAgainstAmputation #DFU #Nutrition @ALPSLimb

A novel inflammation-nutrition biomarker — the neutrophil percentage-to-albumin ratio (NPAR) — shows strong association with diabetic foot ulcer risk in a 1,002-patient study from Xi'an, China, reinforcing that what patients eat and how they inflame are inseparable in the diabetic foot.

0

Your Phone Already Knows What You Can’t Feel: There’s an app for that…A Smartphone App for Detecting Diabetic Neuropathy #ActAgainstAmputation #DPN #DigitalHealth #Neuropathy @JDSTonline @Stanford @ALPSLimb

A Stanford team demonstrates that a smartphone app measuring vibration perception thresholds can detect large-fiber sensory deficits in patients with diabetes — a potential advance for accessible, patient-operated neuropathy screening.

0

Sunday Morning Wish Fulfilled: AI Meets Thermometry in Diabetic Foot Remission — A Scoping Review of 60 Studies #ActAgainstAmputation #AI #Thermography #DFU

A scoping review from Kanazawa University maps 60 studies on AI-powered thermography for diabetic foot detection — and reveals a critical gap: nearly half of all studies were tested only in controlled environments, not the real world where feet actually live.

0

The Pressure Is Worth It: Custom Footwear Guided by In-Shoe Pressure Data Is Cost-Effective for Preventing DFU Recurrence #ActAgainstAmputation #DFU #Remission @DiabetologyMdpi @ALPSLimb

A cost-effectiveness analysis of the DIAFOS trial shows that in-shoe plantar pressure-guided custom footwear saves over €8,000 per ulcer prevented — and adherent patients push the probability of cost-effectiveness to 94%. The economic case for prevention just got stronger.

0

Up ↑

Verified by MonsterInsights